ID
45568
Beskrivning
Principal Investigator: Elaine Mardis, PhD, The Genome Institute, Washington University School of Medicine, St. Louis, MO, USA MeSH: Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000661 This study aims to elucidate the genetic determinants of susceptibility to aggressive prostate carcinoma. To this end, germ line whole exome sequence has been generated from patients with aggressive prostate cancer. Whole genome sequence for a representative subset of tumors from patients whose cancer was resistant to primary therapy is included as well. This deep genomic interrogation will allow the identification of rare, functionally disruptive variants that may play a role in disease progession and response to treatment.
Länk
Nyckelord
Versioner (1)
- 2023-01-23 2023-01-23 - Dr. Christian Niklas
Rättsinnehavare
Elaine Mardis, PhD, The Genome Institute, Washington University School of Medicine, St. Louis, MO, USA
Uppladdad den
23 januari 2023
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs000661 Germline Sequencing for Aggressive Prostate Carcinoma
Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- StudyEvent: SEV1
- Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Subject ID, sample ID, and sample use variable of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Subject ID and race of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Sample ID, body site from which the tissue sample originated, tumor status of sample, and age of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
Similar models
Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- StudyEvent: SEV1
- Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Subject ID, sample ID, and sample use variable of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Subject ID and race of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Sample ID, body site from which the tissue sample originated, tumor status of sample, and age of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
C4684638 (UMLS CUI [1,2])
C0441833 (UMLS CUI [1,2])